Prevention Better Than Cure? AC Immune's Parkinson’s Vaccine Approach
With a broad pipeline focused on neurodegenerative disease, AC Immune is about to begin a Phase II program investigating an alpha-synuclein-targeted peptide vaccine with a diagnostic to stratify patients.
You may also be interested in...
Another hard-to-explain result in Alzheimer’s, with AC Immune claiming the first ever validation of anti-tau therapy, but others are more circumspect.
Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.
Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.